Author: BP Editor
-
Lilly & Novo Nordisk Reach Landmark Pricing Agreement with U.S. Government on Obesity Drugs
As the battle for dominance in obesity treatment intensifies, Eli Lilly and Novo Nordisk are racing ahead with groundbreaking drugs. But with politics and market power in play, the story goes far beyond science — it’s shaping the future of healthcare itself.
-
Bidding War Heats Up: Pfizer vs. Novo Nordisk in the Race to Acquire Metsera
The intense bidding war between Pfizer and Novo Nordisk over Metsera underscores just how fiercely the global obesity-drug market is being contested.
-
Eli Lilly’s Major Netherlands Plant Investment: Scaling Supply for Oral Obesity Therapy
On November 4, 2025, Eli Lilly and Company announced a multi-billion-dollar investment in a new manufacturing facility in the Netherlands to support global rollout of its oral obesity drug orforglipron and fortify its trans-Atlantic production network.
-
The Battle for Metsera: Pfizer and Novo Nordisk in a Fierce Takeover War
As the race for next-generation obesity treatments intensifies, two global pharma giants — Pfizer and Novo Nordisk — are locked in a fierce takeover battle over Metsera, a promising biotech with breakthrough GLP-1 assets. What began as a merger deal has escalated into a high-stakes legal and strategic war.
-
America’s 100% Drug Import Tariff — Reshaping Pharma, Patents and Patients
On September 25, 2025, the White House announced a 100% tariff on imported branded and patented drugs. This policy aims to push pharmaceutical manufacturing back to the U.S. while sparking debate among domestic firms, foreign drugmakers, and patient advocates about costs, supply, and innovation.
-
FDA and HHS Announce Biosimilar Reform — No More Comparative Trials, Full Interchangeability Ahead
The U.S. FDA and HHS have announced a landmark reform to eliminate comparative efficacy trials for biosimilars, aiming to reduce development costs and expand patient access to affordable biologic medicines.
-
Key Pharma & Biotech Trends That Defined 2025
A personal look back at the key pharma and biotech trends that shaped 2025 — from AI-driven drug discovery to mRNA innovation and sustainable healthcare.